Please ensure Javascript is enabled for purposes of website accessibility

Friday's Biggest Health-Care Winner: Illumina, Inc.

By Dave Williamson – Jan 18, 2014 at 5:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Illumina's new machine could be enormous for genome processing, and for investors.

One of the big winners in the health-care space on Friday was Illumina (ILMN 1.27%), up 10% for the day after the company outlined its strategic vision. The big news from the report was its new genome sequencer machine, designed to process a staggering 20,000 genomes a year, at a price point of $1,000. This price has long been a target for the industry, and Illumina's reaching it should lead to widespread use of its machine. Releasing its sequencer now also gets it out ahead of competitor Life Technologies' (NASDAQ: LIFE) $1,000 sequencer, and it positions Illumina to dominate what could be a $20 billion market. In this video, Fool health-care analyst David Williamson tells investors just how big the potential for Illumina in this space could be, and what to watch for from here.

David Williamson has no position in any stocks mentioned. The Motley Fool recommends Illumina. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Illumina Stock Quote
Illumina
ILMN
$220.86 (1.27%) $2.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.